DK3177723T3 - Aptamerer til anvendelse mod autoantistof-associerede sygdomme - Google Patents

Aptamerer til anvendelse mod autoantistof-associerede sygdomme Download PDF

Info

Publication number
DK3177723T3
DK3177723T3 DK15744602.2T DK15744602T DK3177723T3 DK 3177723 T3 DK3177723 T3 DK 3177723T3 DK 15744602 T DK15744602 T DK 15744602T DK 3177723 T3 DK3177723 T3 DK 3177723T3
Authority
DK
Denmark
Prior art keywords
aptamer
receptor
seq
sequence
nucleotide
Prior art date
Application number
DK15744602.2T
Other languages
English (en)
Inventor
Johannes Mueller
Original Assignee
Berlin Cures Holding Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berlin Cures Holding Ag filed Critical Berlin Cures Holding Ag
Application granted granted Critical
Publication of DK3177723T3 publication Critical patent/DK3177723T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B99/00—Subject matter not provided for in other groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Dermatology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)

Claims (18)

1. Aptamer omfattende en nukleotidsekvens, der opfylder en grammatik, som er defineret af sættet af produktionsregler P:
med betingelserne a. ) Q er mængden af naturlige tal b. ) F er en delmængde af naturlige tal, defineret som F := {X e Q | (X > 1)} c. ) Under anvendelse af F defineres: (1) VXe F3M\M -» CXLCX (2) VX e F3K: K —> CXLBX (3) KXe F3V:V^ CXL (4) VX e F: CX —> BXLBX (5) Y VX ^F\BX^Y[G I d. ) U er en mængde af ikke-terminaler, defineret som U = {S, Μ, Ν, D, Ε, γ, Η, R, Ζ, L, ΒΧ, CX, Κ, V} For ΒΧ og CX se c) e. ) W er en mængde af terminaler, defineret som W = {A, C, G, T,G*} Gx betegner alle terminaler, som kan udledes ud fra b.) og c.)(5) f. ) S e U er startsymbolet til anvendelse ved behandling af autoimmune sygdomme forbundet med autoantistoffer mod G-protein-koblede receptorer, hvor "A" betegner et adeninnukleotid, "C" betegner et cytosinnukleotid, "G" betegner et guaninnukleotid, og "T" betegner et thyminnukleotid, hvis nu-kleotidsekvensen er en DNA-sekvens, og "T" betegner et uracilnukleotid, hvis nukleotidsekvensen er en RNA-sekvens, hvor aptameren ikke omfatter nukleotidsekvensen GGTTGGTGTGGTTGG (SEQ ID No: 22), GGTTGGTGTGGT (SEQ ID NO: 23) eller CGCCTAGGT-TGGGTAGGGTGGTGGCG (SEQ ID No: 24), hvor aptameren er til anvendelse ved behandling af en patient, hos hvem autoantistoffer mod G-protein-koblede receptorer kan detekteres, hvor nukleotidsekvensen har en længde på højst 593 nukleotider.
2. Aptamer til anvendelse ifølge krav 1, hvor aptameren anvendes til at inhi-bere interaktionen af autoantistoffer, der er specifikke for en G-protein-koblet receptor, med dens målproteiner.
3. Aptamer til anvendelse ifølge et hvilket som helst af kravene 1 eller 2, hvor nukleotidsekvensen er en DNA-sekvens, eller hvor nukleotidsekvensen er en RNA-sekvens.
4. Aptamer til anvendelse ifølge et hvilket som helst af de foregående krav, hvor nukleotidsekvensen, der er omfattet af aptameren, er en hvilken som helst af følgende sekvenser: (5'-GTTGTTTGGGGTGG-3' SEQ ID No: 1), (5'-GTTGTTTGGGGTGGT-3' SEQ ID No: 2) (5'-GGTTGGGGTGGGTGGGGTGGGTGGG-3' SEQ ID No: 3), (5'-TTTGGTGGTGGTGGTTGTGGTGGTGGTG-3' SEQ ID No: 4), (5'-TTTGGTGGTGGTGGTTGTGGTGGTGGTGG-3' SEQ ID No: 5), (5'-TTTGGTGGTGGTGGTTTTGGTGGTGGTGG-3' SEQ ID No: 6), (5'-TTTGGTGGTGGTGGTGGTGGTGGTGGTGG-3' SEQ ID No: 7), (5'-TTTGGTGGTGGTGGTTTGGGTGGTGGTGG-3' SEQ ID No: 8), (5'-TGGTGGTGGTGGT-3' SEQ ID No: 9), (5'-GGTGGTGGTGG-3' SEQ ID No: 10), (5'-GGTGGTTGTGGTGG-3' SEQ ID No: 11), (5'-GGTGGTGGTGGTTGTGGTGGTGGTGG-3' SEQ ID No: 12), (5-GGT GGT GGTGGTT GTGGT GGT GGT GGTT GT GGTGGTGGT GGTT GT GGT GGT GG TGG-3' SEQ ID No: 13), (5'-GGTGGTTGTGGTGGTTGTGGTGGTTGTGGTGG-3' SEQ ID No:14), (5'-TTTGGTGGTGGTGGTTGTGGTGGTGGTGGTTT-3' SEQ ID No: 15), (5'-GGTGGTGGTGTTGTGGTGGTGGTGGTTT-3' SEQ ID No: 16), (5'-TTTGGTGGTGGTGGTGTGGTGGTGGTGG-3' SEQ ID No: 17), (5'-TGGTGGTGGT-3' SEQ ID No: 18), (5'-TTAGGGTTAGGGTTAGGGTTAGGG (SEQ ID NO: 20).
5. Aptamer til anvendelse ifølge et hvilket som helst af de foregående krav, hvor nukleotidsekvensen af aptameren har en længde på mindst 4 nukleoti-der, fortrinsvis mindst 8 nukleotider, mere foretrukket mindst 12 nukleotider, og/eller hvor nukleotidsekvensen af aptameren har en længde på højst 120 nukleotider, fortrinsvis højst 100 nukleotider, mere foretrukket højst 80 nukleotider.
6. Aptamer til anvendelse ifølge et hvilket som helst af de foregående krav, hvor aptameren kan interagere med et autoantistof, fortrinsvis et autoantistof, som er specifikt for en G-protein-koblet receptor, fortrinsvis specifikt for en hvilken som helst af den humane G-protein-koblede receptor adrenerg alfa-1-receptor, adrenerg beta-1-receptor, adrenerg beta-2-receptor, endothelin 1 ETA-receptor, muskarin M-receptor, angiotensin II AT1 receptor, PAR-receptorer, MAS-receptor, 5HT4-receptor og/eller M3-receptor.
7. Aptamer til anvendelse ifølge et hvilket som helst af de foregående krav, hvor aptameren er til anvendelse som selektiv bestanddel under terapeutisk aferese af blod eller bestanddele deraf fra en patient, der lider af en autoimmun sygdom forbundet med forekomst af autoantistoffer mod G-protein-koblede receptorer.
8. Aptamer til anvendelse ifølge et hvilket som helst af de foregående krav, hvor den autoimmune sygdom er en blandt kardiomyopati, dilateret kardio-myopati (DCM), peripartum kardiomyopati (PPCM), idiopatisk kardiomyopati, iskæmisk kardiomyopati (iCM), Chagas' kardiomyopati, kemoterapi-induceret kardiomyopati, Chagas' megacolon, Chagas' megaoesophagus, Chagas' neuropati, benign prostatahyperplasi, sklerodermi, Raynauds syndrom, præ-eklamsi, perifer okklusiv arteriesygdom (PAOD), nyre-allograft-afstødning, myokarditis, glaukom, hypertension, pulmonal hypertension, malign hypertension, metabolisk syndrom, alopecia, alopecia areata, migræne, Parkinsons sygdom, epilepsi, klyngehovedpine, multipel sklerose, depression, regionalt smertesyndrom, ustabil angina pectoris, systemisk lupus erythematosus (SLE), skizofreni, Sjogrens syndrom, parodontitis, atrieflimren, vitiligo, hæmolytisk uræmisk syndrom, stiff person-syndrom og/eller medfødt hjerteblok.
9. Anvendelse af en aptamer ifølge et hvilket som helst af kravene 1 til 6 eller 8 til in wfro-detektering af et antistof, der er specifikt for en G-protein-koblet receptor, fortrinsvis den humane G-protein-koblede receptor adrenerg alfa-1-receptor, adrenerg beta-1-receptor, adrenerg beta-2-receptor, endothelin 1 ETA-receptor, muskarin M-receptor, angiotensin II AT1-receptor, PAR-receptorer, MAS-receptor, 5HT4-receptor og/eller M3-receptor, hvor antistoffet, der skal detekteres, er et autoantistof.
10. Anvendelse af aptameren ifølge krav 9, hvor antistoffet er til stede i eller stammer fra en kropsvæske, fortrinsvis en væske fra en menneskekrop, mere foretrukket humant blod, plasma, serum, urin, fæces, synovialvæske, in-terstitiel væske, lymfe, spyt, spinalvæske og/eller tårevæske.
11. Anvendelse af aptameren ifølge krav 10, hvor kropsvæsken udtages fra en person, der lider af eller mistænkes for at lide af en autoimmun sygdom, fortrinsvis en autoimmun sygdom forbundet med tilstedeværelse i serum hos patienten af autoantistoffer, der er specifikke for en G-protein-koblet receptor, mere foretrukket autoimmune sygdomme forbundet med tilstedeværelse i serum hos patienten af autoantistoffer, der er specifikke for adrenerg alfa-1-receptor, adrenerg beta-1-receptor, adrenerg beta-2-receptor, endothelin 1 ETA-receptor, muskarin M-receptor, angiotensin II AT1-receptor, PAR-receptorer, MAS-receptor, 5HT4-receptor og/eller M3-receptor.
12. Aptamer til anvendelse ifølge et hvilket som helst af kravene 1 til 8, hvor aptameren omfatter følgende nukleotidsekvens (5'-GGTGGTGGTGGTTGTGGTGGTGGTGG-3' SEQ ID No. 12).
13. Anvendelse af aptameren ifølge et hvilket som helst af kravene 9 til 11, hvor aptameren omfatter følgende nukleotidsekvens (5'-GGTGGTGGTGGTTGTGGTGGTGGTGG-3' SEQ ID No. 12).
14. Farmaceutisk sammensætning omfattende mindst en aptamer ifølge et hvilket som helst af kravene 1 til 8 og, eventuelt, mindst en farmaceutisk acceptabel excipiens til anvendelse ved behandling af autoimmune sygdomme forbundet med autoantistoffer mod G-protein-koblede receptorer, hvor aptameren er til anvendelse ved behandling af en patient, hos hvem autoantistoffer mod G-protein-koblede receptorer kan detekteres.
15. Farmaceutisk sammensætning til anvendelse ifølge krav 14, hvor den farmaceutiske sammensætning omfattende aptameren anvendes til at inhibe-re interaktionen af autoantistoffer, der er specifikke for en G-protein-koblet receptor, med dens målproteiner.
16. Aferese-søjle omfattende en aptamer ifølge et hvilket som helst af de foregående krav til anvendelse ved behandling af en autoimmun sygdom, hvor den autoimmune sygdom er kardiomyopati, dilateret kardiomyopati (DCM), peripartum kardiomyopati (PPCM), idiopatisk kardiomyopati, iskæmisk kardiomyopati (iCM), Chagas' kardiomyopati, kemoterapi-induceret kardiomyopati, Chagas' megacolon, Chagas' megaoesophagus, Chagas' neuropati, benign prostatahyperplasi, sklerodermi, Raynauds syndrom, perifer okklusiv arteriesygdom (PAOD), præeklamsi, nyre-allograft-afstødning, myokarditis, glaukom, hypertension, pulmonal hypertension, malign hypertension, metabolisk syndrom, alopecia, alopecia areata, migræne, Parkinsons sygdom, epilepsi, klyngehovedpine, multipel sklerose, depression, regionalt smertesyndrom, ustabil angina pectoris, systemisk lupus erythematosus (SLE), skizofreni, Sjogrens syndrom, parodontitis, atrieflimren, vitiligo, hæmolytisk uræmisk syndrom, stiff person-syndrom og/eller medfødt hjerteblok, hvor aptameren er til anvendelse ved behandling af en patient, hos hvem autoantistoffer mod G-protein-koblede receptorer kan detekteres.
17. Aferese-søjle til anvendelse ifølge krav 16, hvor aptameren anvendes som selektiv bestanddel til specifikt at udskille de autoantistoffer, som aptameren specifikt er rettet imod.
18. Fremgangsmåde til fremstilling af en aptamer-oligonukleotid, omfattende følgende trin: I) bestemmelse af en nukleotidsekvens til anvendelse som en aptamerse-kvens omfattende anvendelse af følgende sæt af produktionsregler P:
med betingelserne a. ) Q er mængden af naturlige tal b. ) F er en delmængde af naturlige tal, defineret som F := {X € Q I (X > 1)} c. ) Under anvendelse af F defineres: (1) vXe F3M: M—> CXLCX (2) vXe F3K \K-> CXLBX (3) VXe FlV\V-> CXL (4) VXe F: CX-> BXLBX (5) .Y VXeF: 1 d. ) U er en mængde af ikke-terminaler, defineret som U = {S, Μ, N, D, E, Y, H, R, Z, L, BX, CX, K, V} For BX og CX se c) e. ) W er en mængde af ikke-terminaler, defineret som W = {A, C, G, T, Gx} Gx betegner alle terminaler, som kan udledes ud fra b.) og c.)(5) f. ) S e U er startsymbolet hvor "A" betegner et adeninnukleotid, "C" betegner et cytosinnukleotid, "G" betegner et guaninnukleotid, og "T" betegner et thyminnukleotid, hvis nu-kleotidsekvensen er en DNA-sekvens, og "T" betegner et uracilnukleotid, hvis nukleotidsekvensen er en RNA-sekvens, hvor nukleotidsekvensen til anvendelse som en aptamersekvens ikke omfatter nukleotidsekvensen GGTTGGTGTGGTTGG (SEQ ID No: 22), GGT-TGGTGTGGT (SEQ ID NO: 23) eller CGCCTAGGTTGGGTAGGGTGGT-GGCG (SEQ ID No: 24), hvor nukleotidsekvensen til anvendelse som en aptamersekvens har en længde på højst 593 nukleotider, og II) produktion af en aptamer-oligonukleotid med nukleotidsekvensen opnået i trin I).
DK15744602.2T 2014-08-04 2015-08-04 Aptamerer til anvendelse mod autoantistof-associerede sygdomme DK3177723T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14179715.9A EP2982756A1 (en) 2014-08-04 2014-08-04 Aptamers for use against autoantibody-associated diseases
PCT/EP2015/067951 WO2016020377A1 (en) 2014-08-04 2015-08-04 Aptamers for use against autoantibody-associated diseases

Publications (1)

Publication Number Publication Date
DK3177723T3 true DK3177723T3 (da) 2018-02-12

Family

ID=51302898

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15744602.2T DK3177723T3 (da) 2014-08-04 2015-08-04 Aptamerer til anvendelse mod autoantistof-associerede sygdomme

Country Status (11)

Country Link
US (1) US20170226513A1 (da)
EP (2) EP2982756A1 (da)
JP (4) JP6630356B2 (da)
CN (3) CN117230073A (da)
AU (1) AU2015299059B2 (da)
BR (1) BR112017002270B1 (da)
CA (1) CA2956877C (da)
DK (1) DK3177723T3 (da)
ES (1) ES2658492T3 (da)
PL (1) PL3177723T3 (da)
WO (1) WO2016020377A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3446714B1 (en) 2011-06-02 2021-03-31 University of Louisville Research Foundation, Inc. Anti-nucleolin agent-conjugated nanoparticles
EP2982756A1 (en) * 2014-08-04 2016-02-10 Berlin Cures Holding AG Aptamers for use against autoantibody-associated diseases
CN109451729B (zh) 2016-06-08 2022-03-22 哈佛学院院长及董事 工程化病毒载体减少了炎症和免疫反应的诱导
WO2019094548A1 (en) 2017-11-08 2019-05-16 President And Fellows Of Harvard College Compositions and methods for inhibiting viral vector-induced inflammatory responses
WO2020086895A1 (en) * 2018-10-24 2020-04-30 Scivera LLC Computer-implemented method for quantifying chemical hazard assessment
EP3715374A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the sequestration of undesirable antibodies in a patient
US11986536B2 (en) 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
EP3715376A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the prevention or treatment of myasthenia gravis
EP3715375A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the prevention or treatment of pre-eclampsia
MX2023003375A (es) 2020-09-23 2023-03-31 Ablevia Biotech Gmbh Compuesto para aumentar la eficacia de la terapia de sustitucion del factor viii.
AU2021347583A1 (en) 2020-09-23 2023-05-25 Ablevia Biotech Gmbh Compound for increasing efficacy of viral vectors
EP4216990A1 (en) 2020-09-23 2023-08-02 Ablevia biotech GmbH Compound for the sequestration of undesirable antibodies in a patient
TW202228784A (zh) 2020-09-23 2022-08-01 奧地利商艾柏力維亞生技有限公司 用以於一患者中螯合非預期的抗ｐｅｇ抗體的化合物
JP2023542389A (ja) 2020-09-23 2023-10-06 アブレヴィア バイオテック ゲーエムベーハー 自己抗体で媒介される状態の予防又は治療のための化合物
KR20230074552A (ko) 2020-09-24 2023-05-30 아블레비아 바이오테크 게엠베하 중증 근무력증의 예방 또는 치료용 화합물
CN113588937A (zh) * 2021-07-19 2021-11-02 刘艳 一种心肌细胞m3受体的检测方法
CN114533889B (zh) * 2022-02-25 2023-05-26 中南大学 一种DNA功能化PBNPs纳米酶制备方法和在靶向光热治疗剂制备中的应用
WO2023180502A1 (en) 2022-03-24 2023-09-28 Ablevia Biotech Gmbh Compound for increasing efficacy of oncolytic viruses
WO2024038918A1 (ja) * 2022-08-19 2024-02-22 国立大学法人東京農工大学 一本鎖抗体結合アプタマー

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2590799A (en) * 1998-02-19 1999-09-06 Ortho-Mcneil Pharmaceutical, Inc. Azole peptidomimetics as thrombin receptor antagonists
WO1999065928A2 (en) * 1998-06-19 1999-12-23 Genzyme Corporation Polynucleotide population isolated from non-metastatic and metastatic breast tumor tissues
ES2296615T3 (es) * 1999-04-08 2008-05-01 Antisoma Research Limited Actividad antiproliferativa de oligonucleotidos ricos en g y procedimiento de uso de los mismos para su union a la nucleolina.
WO2002068425A1 (en) * 2001-02-23 2002-09-06 Ortho-Mcneil Pharmaceutical, Inc. Aminomethyl-pyrroloquinazoline compounds as thrombin receptor antagonists
WO2005037323A2 (en) 2003-10-10 2005-04-28 University Of Louisville Research Foundation, Inc. Use of gro to treat or prevent inflammation
AU2006283025A1 (en) 2005-08-26 2007-03-01 Archemix Corp. Aptamers that bind thrombin with high affinity
US20090131351A1 (en) * 2007-11-16 2009-05-21 Antisoma Research Limited Methods, compositions, and kits for modulating tumor cell proliferation
WO2011133142A1 (en) * 2010-04-20 2011-10-27 University Of Louisville Treatment of vhl-negative tumors
EP2402016A1 (en) 2010-06-29 2012-01-04 Charité - Universitätsmedizin Berlin Aptamers that inhibit interaction between antibody and 1st or 2nd extracellular loop of human beta-1-adrenergic receptor
EP2497828A1 (en) * 2011-03-07 2012-09-12 Charité - Universitätsmedizin Berlin Use of aptamers in therapy and/or diagnosis of autoimmune diseases
EP2982756A1 (en) * 2014-08-04 2016-02-10 Berlin Cures Holding AG Aptamers for use against autoantibody-associated diseases

Also Published As

Publication number Publication date
CN117230073A (zh) 2023-12-15
AU2015299059B2 (en) 2017-08-03
JP2023022189A (ja) 2023-02-14
CA2956877C (en) 2019-06-25
JP2017529872A (ja) 2017-10-12
BR112017002270A2 (pt) 2018-01-16
PL3177723T3 (pl) 2018-05-30
JP2018171070A (ja) 2018-11-08
JP7267689B2 (ja) 2023-05-02
WO2016020377A1 (en) 2016-02-11
US20170226513A1 (en) 2017-08-10
EP2982756A1 (en) 2016-02-10
AU2015299059A1 (en) 2017-03-02
CA2956877A1 (en) 2016-02-11
EP3177723B1 (en) 2017-12-06
CN117247941A (zh) 2023-12-19
JP2021035369A (ja) 2021-03-04
EP3177723A1 (en) 2017-06-14
JP6630356B2 (ja) 2020-01-15
ES2658492T3 (es) 2018-03-12
CN106795516A (zh) 2017-05-31
BR112017002270B1 (pt) 2020-11-24

Similar Documents

Publication Publication Date Title
DK3177723T3 (da) Aptamerer til anvendelse mod autoantistof-associerede sygdomme
US10266830B2 (en) Use of aptamers in therapy and/or diagnosis of autoimmune diseases
EP2588115B1 (en) Aptamers that inhibit interaction between antibody and 2nd extracellular loop of human beta-1-adrenergic receptor